explore -WSS

explore

author：leisure time 2025-09-27 10:05:57 - browse：59264

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Menendez indictment could see pharma lose a key ally

hotspot

WSS

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

Climate activists disrupt London Pride march to protest corporate sponsorship

Scientists find bacteria from stomach of ancient iceman

Why do women spend more than men on medical expenses?

Jailed Russian opposition leader Alexey Navalny gets 19 more years in prison

explore

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Walensky prepares to leave CDC — and Congress — behind

Scientists find bacteria from stomach of ancient iceman

Novavax promises a turnaround & Lilly roils the obesity market

Sudafed saga points to U.S. issues with evaluating older drugs

Guidelines to prevent youth baseball injuries need more muscle

Eat, drink, but be wary — 4 foods that interact with medications

Anesthesiologist group: stop taking Ozempic before surgery

Covid vaccines: Private market messier than government rollout

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

hotspot

Special counsel alerts court to Trump’s social media post

Paxlovid should be available without a positive Covid test

Shingles, which affected Dianne Feinstein, is on the rise

Scientists find bacteria from stomach of ancient iceman

Data show record exodus of life scientists from academia

Ionis has late

entertainment

hotspot

hotspot

Wikipedia